WAKEFIELD, MA / ACCESSWIRE / June 23, 2022 / Innovation Pharmaceuticals (OTCQB: IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron (B.1.1.529) and Delta (B.1.617.2 ) variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma (P.1) and Alpha (B.1.1.7) variants of SARS-CoV-2.
Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS -CoV-1. Brilacidin is consistently inhibited by all coronaviruses tested, independent of cell type, generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin).
Identifying COVID-19 countermeasures with novel mechanisms of action is vital. SARS-CoV-2 continues to evolve at the accelerated pace, raising questions as to what the dominant variant (or sub-variant) may be this fall and winter, when infections often spike – and if today’s COVID-19 vaccines and therapeutics can maintain their effectiveness.
Emerging SARS-CoV-2 variants, and their sub-variants, contain immunity-evading mutations. These mutations alter key parts of the SARS-CoV-2 spike protein that binds to human cells, making the virus more transmissible and potentially more virulent. Like other monoclonal antibodies, Brilacidin has not been shown to target the Spike S1 and Spike RBD regions of SARS-CoV-2, acting instead through dual-acting neutralizing and blocking antiviral properties, able to target virus and host. These antiviral traits support Brilacidin’s ability to maintain its anti-coronavirus activity and suggest Brilacidin would be less subject to resistance.
Related, results from new NIH / NIAID in vitro testing of Brilacidin in over 20 acutely infectious viruses, and from the Brilacidin Phase 2 COVID-19 clinical trial, are being prepared for publication. Findings from the Rutgers’ Brilacidin research can be accessed at the link below1 and build on earlier published Brilacidin research conducted by scientists at George Mason University and at the University of Arizona and University of California-San Francisco.
In 2021, the Company completed a Phase 2 clinical trial of Brilacidin (NCT04784897) for the treatment of moderate-to-severe COVID-19 patients. While the trial did not meet its primary endpoint, Brilacidin for that primary endpoint did. For example, patients treated early on onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p = 0.03). To date, only a modicum of success has been promoted by any company conducting clinical trials in COVID-19. The patient may be affected by the changes in the standard of care of patients receiving a cocktail of fluctuating concomitant medications, which complicates the interpretation of the clinical trial data and that of the new drug candidate being evaluated. Clinical observations of COVID-19 patients treated with Brilacidin
Taken together, the results from the NIH / NIAID testing of Brilacidin are supportive of the compound’s antiviral potential. The Company remains active in further government-based funding opportunities, in advance of the treatment of viral diseases.
1Theresa L Chang, et al. “Brilacidin, a Non-Peptide Defensin-Mimetic Molecule, Inhibits SARS-CoV-2 Infection by Blocking Viral Entry.” EC Microbiol. 2022 Apr; 18 (4): 1-12.
Sign-up for Innovation Pharmaceuticals email alerts is available at:
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory, cancer, and infectious diseases. The Company is also active in identifying other potential investment opportunities that can add value and diversify its portfolio.
Forward-Looking Statements: This press release contains forward-looking statements made by the Federal Securities Litigation Reform Act of 1995 including, without limitation, statements concerning future product development plans, including with respect to specific indications; statements regarding the therapeutic potential and capabilities of the StingRay System; future regulatory developments; and any other statements which are other than statements of historical fact. These forward looking statements The Company has in some cases identified forward looking statements such as “anticipates,” “considers,” “hopes,” “estimates,” “looks,” “expectations,” “plans,” “intends,” “goal , “” potential, “” may, “” suggest, “and similar expressions. Among other factors that could cause actual results to be carried out in the United States and other jurisdictions, including without limitation that compounds and devices may not be successfully completed in the United States or elsewhere; a priori test results may not be replicated in future studies and trials; the Company’s need for, and the availability of, substantial capital in the future to its operations and research and development, including the amount and timing of the sale of common stock under securities purchase agreements; and the Company’s licensee (s) may not receive milestone payments. A more complete description of these and other risk factors is included in the Company’s filings with the Securities and Exchange Commission. Many of these risks, uncertainties and threats are beyond the Company’s ability to control or predict. You should not place undue reliance on any forward-looking statements. The Company has only been made available to do so by the Company, which has no obligation to disclose the results. events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law or regulation.
INVESTOR AND MEDIA CONTACTS
Innovation Pharmaceuticals Inc.
SOURCE: Innovation Pharmaceuticals Inc.
View source version on accesswire.com: